To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer

Non-squamous Cell Non-small Cell Lung Cancer Clinical Trial

Official title:

to Evaluate SCT510 Compared to Avasitin Respectively Combined Paclitaxel and Carboplatin First-line Treatment of Locally Advanced and Metastatic or Recurrent Squamous Cell Non-small Cell Lung Cancer Efficacy and Safety

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03792074
• Other study ID #: SCT510-A301
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: February 2019
• Est. completion date: January 2022

Study information

• Verified date: December 2018
• Source: Sinocelltech Ltd.
• Contact: ming gao
• Phone: 8618610163675
• Email: ming_gao[@]sinocelltech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety, efficacy and immunogenicity of SCT510 combined with paclitaxel and carboplatin compared with bevacizumab combined with paclitaxel and carboplatin in the first-line treatment of locally advanced metastatic or recurrent squamous cell non-small cell lung cancer.

Description:

A randomized, double-blind, parallel-controlled, multicenter phase 3 clinical trial.

560 patients with non-resectable locally advanced, metastatic or recurrent non-squamous cell non-small cell lung cancer (NSCLC) were randomly divided into two groups (SCT510 group and bevacizumab group) at a 1:1 ratio, and the treatment included combination chemotherapy and maintenance treatment, followed by follow-up.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 560
• Est. completion date: January 2022
• Est. primary completion date: May 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Volunteer to participate in this study and sign the informed consent;

2. age is = 18 years old and = 80 years old, regardless of gender;

3. Subjects with unresectable locally advanced metastatic(Not suitable for the multidisciplinary treatment ? B - ? period of subjects, according to the international association for the study of lung cancer (IASLC) lung cancer staging manual version 8 standard judgment) or recurrent non-squamous cell non-small cell lung cancer diagnosed by histological and/or cytological examination.The diagnosis of non-squamous cell non-small cell lung cancer based on sputum cytology requires immunohistochemical confirmation.If multiple tumor components are mixed, the main cell types are classified.

4. It is able to provide relevant documents about EGFR mutation and ALK fusion gene status, and there is no EGFR sensitive mutation (including exon mutation no. 18 (G719X), exon deletion no. 19 and exon mutation no. 21 (L858R, L861Q)) and ALK fusion.Subjects who have not previously undergone EGFR and ALK gene testing will need to undergo genetic testing during the screening period.Among them, subjects whose EGFR or ALK gene status cannot be determined for various reasons can be enrolled;Subjects who are known to have EGFR sensitive mutations and/or ALK fusion may also be enrolled if they are currently unable to obtain the corresponding targeted drugs (including the rejection of the subjects) and chemotherapy is standard treatment at the research center;

5. According to RECIST v1.1 criteria, at least one measurable lesion was ensured;The lesions that had received radiotherapy before could only be selected as target lesions if there was clear disease progression 3 months after the end of radiotherapy.

6. Systemic antitumor therapy for locally advanced metastatic or recurrent non-squamous non-small cell lung cancer has not been accepted.If the subjects in the complete early non-small cell lung cancer after radical treatment received adjuvant therapy, and disease relapse, participants need to ensure that adjuvant therapy over time from this study first dosing interval more than 6 months, and auxiliary treatment led to a variety of toxic effects have been restored (according to the CTCAE v4.03 standard judgment level 1 or less, except for hair loss).

7. Eastern Cooperative Oncology Group (ECOG) physical condition score 0 or 1

8. the expected survival time is more than 6 months;

9. Laboratory inspection meets the following requirements:

• absolute neutrophil value (ANC) is greater than 1.5 x 109/L, platelet count (PLT) is greater than 100 x 109/L, hemoglobin (HGB) is greater than 90 g/L, and white blood cell (WBC) is greater than 3.0 x 109/L;

• liver function: total bilirubin (TBil) < 1.5 times the normal upper limit; Aspartate aminotransferase(AST/SGOT),Alanine aminotransferase (ALT/SGPT),andalkaline phosphatase(ALP) < 2.5 times the normal upper limit;In the case of liver metastasis, AST and ALT were less than or equal to 5.0 times the upper limit of normal values.In the case of liver metastasis and/or bone metastasis, ALP is less than or equal to 5.0 times the normal upper limit.

• renal function: upper limit of normal serum creatinine (Scr) less than 1.5 times;

• urine protein < 2 (+) detected by routine urine test;If the urine protein at baseline is greater than or equal to 2 (+), the 24-hour urine protein quantification must be less than or equal to 1.0 g.

• coagulation function: the international standardized ratio (INR) is no more than 1.5, and the activation time of partial thrombin (APTT) is no more than 1.5 times the upper limit of normal value;

10. Heart function: left ventricular ejection fraction (LVEF) 50% or higher;

11. able to communicate well with researchers and follow the visit, treatment, laboratory examination and other relevant regulations stipulated in the study.

Exclusion Criteria:

1. subjects with mixed non-small cell and small cell carcinoma, squamous cell carcinoma or mixed adenosquamous carcinoma with squamous cell as the main component

2. patients with a history of tracheoesophageal fistula, gastrointestinal perforation or gastrointestinal fistula and intraperitoneal abscess within 6 months before randomization;

3. patients with malignant tumors other than lung cancer within the first 5 years were randomized, excluding cured carcinoma in situ of the cervix, skin basal cells cancer or squamous epithelial cells skin cancer, local prostate cancer after radical resection and ductal carcinoma in situ of the breast after radical resection;

4. severe cardiovascular and cerebrovascular diseases, including cerebrovascular accidents (CVA), transient ischemic attack (TIA), myocardial infarction and significant vascular diseases (including but not limited to aortic aneurysms requiring surgical repair or recent arterial thrombosis) within the first 6 months randomly;Patients with unstable angina, New York heart association (NYHA) classification = ? heart failure and arrhythmia drugs can't control;

5. Subjects who received lung radiotherapy within the first 4 weeks or who had not recovered from radiation-related toxicity were randomized.For all other anatomical sites, subjects received radiotherapy within the first 2 weeks of randomization or did not recover from radiation-related toxicity;

6. Major surgery was performed within the first 4 weeks of randomization or major surgical treatment was planned during the trial period (the researchers determined that there was a risk of bleeding or wound healing complications);

7. Have bleeding tendency, high bleeding risk or coagulation dysfunction, including thrombotic disease within 6 months prior to randomization and/or hemoptysis history within 3 months prior to randomization (single hemoptysis is more than 2.5mL);Or recently (less than 10 days after the first study drug treatment) using a full dose oral or extralimental anticoagulant or thrombolytic agent or aspirin (> 325 mg/ day) or other nsaids that inhibit platelet function;Or prior to surgery, the researchers determined that there was a tendency to bleed;

8. subjects with high suspicion of idiopathic pulmonary fibrosis, organic pneumonia, drug-related pneumonia, idiopathic pneumonia or active pneumonia in chest CT scan during the screening period;

9. subjects with known central nervous system metastasis (except asymptomatic brain metastasis and subjects with treated symptoms controlled and stable symptoms within 1 month prior to randomization).Patients with clinical suspected central nervous system metastasis must undergo enhanced CT or MRI within the first 28 days randomly to exclude central nervous system metastasis.

10. imaging examination showed signs of tumor invasion into the large blood vessel, and the tumor had completely approached, wrapped or invaded the large blood vessel cavity (such as pulmonary artery or superior vena cava);

11. patients with hypertension (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg) who are still under poor control after combined treatment with two or more antihypertensive drugs in the screening period, as well as those who have a history of hypertension crisis or hypertensive encephalosis;

12. The presence of unhealed wounds, active peptic ulcers and fractures (excluding healed old fractures);

13. There is a large amount of pericardial effusion, peritoneal or pleural effusion that cannot be controlled by drainage or other symptomatic treatment (symptomatic treatment is allowed before enrollment, but drugs with anti-tumor indications, such as chemotherapy drugs, anti-angiogenic drugs and molecular targeted drugs, cannot be given);

14. HBsAg is positive, and the titer detection of HBV-DNA in peripheral blood = 1x103 copy number /mL (or the quantitative determination of HBV-DNA =200 units /mL); HCV or HIV or syphilis positive subjects;At present, there are other active infectious diseases, which are not suitable for inclusion in this study.

15. known for SCT510, bevacizumab, paclitaxel and carboplatin injection and its material composition allergies;

16. women who are pregnant or breast-feeding;

17. women of child-bearing age or male subjects who are unwilling to take effective contraceptive measures during the study period or within 6 months after the last administration of the study drugs;

18. subjects who have participated in other clinical studies in the first 4 weeks of randomization or who are receiving treatment in other clinical trials (except those who participated in the overall survival follow-up of one study);

19. previous history of alcoholism or drug abuse;

20. in addition to the above circumstances, the researcher believes that there are other circumstances that are not suitable for inclusion.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-squamous Cell Non-small Cell Lung Cancer

Intervention

Drug:
• SCT510
SCT510 Injection
• Bevacizumab
Bevacizumab Injection
• Paclitaxel
Paclitaxel Injection
• Carboplatin
Carboplatin injection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sinocelltech Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate	the proportion of subjects whose CR(complete response) and PR(partial response)combined , according to RECIST 1.1 criteria	12 weeks
Secondary	Objective response rate	the proportion of subjects whose CR(complete response) and PR(partial response)combined , according to RECIST 1.1 criteria	18 week
Secondary	Disease control rate	the proportion of subjects with CR(complete response), PR(partial response) and SD(Stable disease) combined,according to RECIST 1.1 criteria	12 weeks and 18 weeks
Secondary	Duration of Response	The time from the first assessment of CR(complete response) or PR(partial response) to the first assessment of PD(progressive disease) or any cause of death,according to RECIST 1.1 criteria	3 years
Secondary	Progression free survival	The time from randomization to PD(progressive disease) or any cause of death,according to RECIST 1.1 criteria	3 years
Secondary	1-year overall survival rate	The proportion of subjects who survived longer than 1 year after randomization	1 year
Secondary	Overall survival	Defined as the time from randomization of subjects to death from any cause	3 years